#USA #oncology #Pittsburgh #ADCs #Myris Therapeutics

Myris Therapeutics: Pioneering Ultra-High DAR ADCs in Oncology

Introduction
Myris Therapeutics has made a remarkable entry into the biotech field, unveiling its groundbreaking approach to targeted cancer therapies. Formerly recognized as BioHybrid Solutions, the company has restructured its vision, focusing on the development of ultra-high Drug Antibody Ratio (DAR) antibody-drug conjugates (ADCs). This strategic shift is poised to revolutionize how oncology treatments are approached, offering new possibilities in precision medicine.

A New Era in Cancer Treatment
On February 20, 2025, Myris Therapeutics emerged from stealth mode, highlighting a novel pipeline that leverages proprietary polymer chemistry to achieve drug-to-antibody ratios unprecedented in the industry. With capabilities of DAR50-300, Myris can incorporate between 50 to 300 drug molecules per antibody. This development not only enhances the payload capacity significantly—by 10 to 100 times more than current standards—but also widens the therapeutic options available for targeted treatment strategies.

Dr. Laura Benjamin, CEO of Myris Therapeutics, emphasizes the potential this technology holds: "This dramatically expands the range of possible payloads and precision therapy opportunities. Many clinically validated small molecules, previously unsuitable for ADCs due to pharmacological limitations, can now be re-evaluated for use, thereby enhancing efficacy and tolerability in treatment."

Leadership and Expertise
Dr. Laura Benjamin brings a wealth of experience to her role as CEO, having previously steered the clinical developments at OncXerna. Her leadership is reinforced by a strong scientific advisory board, including renowned experts like Dr. Patrick Zweidler-McKay and Dr. Pasi Janne. Their extensive backgrounds in oncology and ADC development ensure Myris is well-positioned to tackle the challenges of translating scientific concepts into therapeutically viable products.

Technological Foundation
At the heart of Myris Therapeutics lies its sophisticated polymer technology, which was initially used to enhance therapeutic enzymes. This pioneering work continues to influence Myris' ADC capabilities, with co-founder Krzysztof Matyjaszewski, a leader in polymer science, actively guiding the scientific direction of the company.

The company has further bolstered its internal capabilities by recruiting experienced professionals across various functions, including Becky Wolfe as COO and Jeffrey S. Humphrey as CMO. Their combined expertise will play a vital role in navigating the complexities of bringing these innovative therapies to market.

Pipeline and Partnerships
Myris Therapeutics is not starting from scratch; the legacy programs from BioHybrid Solutions are currently advancing towards clinical trials. The company has secured funding from the Department of Defense for its lead program, successfully nominating a development candidate. Such financial backing underscores the trust in Myris's vision and capabilities.

Future Outlook
Myris Therapeutics is set to present its ADC technology at the upcoming AACR conference in Chicago, a key platform for the company to showcase its advancements. As the cancer treatment landscape continues to evolve, Myris stands at the forefront, armed with innovative solutions that hold the promise of changing lives.

Conclusion
With its game-changing approach to ADC development, Myris Therapeutics is not just another biotech company; it is a trailblazer in precision oncology. As they continue to innovate and refine their technology, the potential for more effective, targeted therapies has never been more tangible. For further updates, interested parties can follow Myris on their official platforms or visit their website at myristx.com.